Movement Alert｜10x Genomics, Inc. Intraday Rise 5.16% in Regular Trading, recent analyst target-price resets remain in focus

Market Focus10-27 22:35

On October 27, 10x Genomics, Inc. rose 5.16% in Regular Trading, trading at $76.59 per share, with turnover of $17.95 million.

A clear recent catalyst in public information is analyst activity: Stephens downgraded the stock to Equal Weight on October 23 while setting a $65 price target, following BofA Securities' October 9 increase in its price target to $80 from $50.

The broader backdrop is mixed but supportive of continued investor attention. Earlier, the company began commercial shipments of its Atera spatial biology platform on September 29 and announced a multi-project collaboration with Fred Hutchinson Cancer Center on October 7 focused on biomarker discovery and residual disease detection. In August, 10x Genomics reported quarterly revenue of $151.0 million versus $146.7 million expected, with a per-share loss of $0.14 versus a $0.24 loss expected, and lifted full-year revenue guidance to $610 million-$630 million.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment